Clinical Trials
2 trialsNCT06876142 2026-05-27
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Suspended
NCT04505813 2024-01-16
Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma
NexImmune Inc.
Phase 1/2 Suspended